Abstract
The efficacy of triclabendazole in the treatment of chronic Fasciola infection was assessed. A total of 134 asymptomatic cases of established Fasciola infection were treated: 68 individuals received a single dose of 10 mg/kg and 66 individuals received 2 doses of 10 mg/kg on 2 consecutive days. Cure was assessed 5 weeks after treatment and 79.4% of the first group and 93.9% of the second group were cured. The drug was well tolerated; no serious side-effects were noted. One patient developed biochemical cholestasis the third day after treatment, but her enzyme profiles returned to normal after 2 months. We conclude triclabendazole is a safe and potent fasciolicidic drug.
Publication types
-
Clinical Trial
-
Comparative Study
-
Randomized Controlled Trial
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Adolescent
-
Adult
-
Anthelmintics / administration & dosage*
-
Anthelmintics / adverse effects
-
Benzimidazoles / administration & dosage*
-
Benzimidazoles / adverse effects
-
Child
-
Child, Preschool
-
Cholestasis / chemically induced
-
Cholestasis / enzymology
-
Chronic Disease
-
Drug Administration Schedule
-
Egypt / epidemiology
-
Endemic Diseases / prevention & control
-
Fascioliasis / drug therapy*
-
Fascioliasis / epidemiology
-
Fascioliasis / parasitology
-
Female
-
Humans
-
Liver Function Tests
-
Male
-
Middle Aged
-
Treatment Outcome
-
Triclabendazole
Substances
-
Anthelmintics
-
Benzimidazoles
-
Triclabendazole